Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUSPENSION, EXTENDED RELEASEGeneric

PALIPERIDONE PALMITATE

PALIPERIDONE PALMITATE

Standard Dose
39MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview PALIPERIDONE PALMITATE is listed in Drugs@FDA under application 216674 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient PALIPERIDONE PALMITATE Form and strength INJECTABLE; SUSPENSION, EXTENDED RELEASE - 39MG Sponsor ACCORD HLTHCARE INC Submission history Latest submission status date: 2025-05-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview PALIPERIDONE PALMITATE is listed in Drugs@FDA under application 216674 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient PALIPERIDONE PALMITATE Form and strength INJECTABLE; SUSPENSION, EXTENDED RELEASE - 39MG Sponsor ACCORD HLTHCARE INC Submission history Latest submission status date: 2025-05-16 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.